Exploring Top 20 Companies in the Acetazolamide Market: Emerging Market Trend, Key Market Insights and Future Prospects (2024–2035)

According to a research report published by Spherical Insights & Consulting, the Global Acetazolamide Market Size is projected to grow from USD 214.6 million in 2024 to USD 352.7 million by 2035, at a CAGR of 4.62% during the forecast period of 2025–2035. The market is driven by increasing rates of glaucoma are also expected to aid market growth as acetazolamide is effective at lowering eye pressure to prevent eye damage from glaucoma. The market segmentation includes tablets, capsules, and injections, with key applications being glaucoma, epilepsy, edema, altitude sickness, fluid retention, heart failure, and seizures.

Introduction

The acetazolamide market operates within the pharmaceutical sector through its activities, which include developing, distributing and selling acetazolamide products. The drug functions as a carbonic anhydrase inhibitor, which belongs to this medication class. The market size of acetazolamide exists because the drug handles medical disorders that occur worldwide, while the drug itself remains in demand across different regions. Acetazolamide tablets serve three primary medical purposes, which include glaucoma management through intraocular pressure reduction and altitude sickness prevention and treatment through acclimatization support.

The Indian pharmaceutical market is projected to reach USD 65-70 billion by 2024-25, which creates substantial business prospects, but only 30% of Indian pharmaceutical manufacturers have obtained WHO GMP certification for their production facilities.

 

Navigate Future Markets with Confidence: Insights from Spherical Insights LLP

The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the acetazolamide market.

 

Global Acetazolamide Market Size & Statistics

• The Market Size for Global Acetazolamide was Estimated to be worth USD 214.6 million in 2024.
• The Market is Going to Expand at a CAGR of 4.62% between 2025 and 2035.
• The Global Acetazolamide Market Size is anticipated to reach USD 352.7 million by 2035.
• Asia Pacific is expected to generate the highest demand during the forecast period in the global Acetazolamide market.
• North America is expected to grow the fastest during the forecast period in the Global Acetazolamide Market.

 

Regional Growth and Demand

Asia Pacific is expected to grow the largest during the forecast period in the global acetazolamide market. Asia Pacific is expected to generate the highest demand due to the availability of several drug manufacturing companies in the region. Availability of the large patient pool for several diseases, and government support to provide basic medicine at a low price is boosting the demand for the acetazolamide products in the region.

 

North America is expected to generate the fastest demand during the forecast period in the global acetazolamide market. North America is projected to grow fastest due to its advanced healthcare infrastructure and a high prevalence of glaucoma and epilepsy. The presence of leading pharmaceutical companies and a robust distribution network further support the market in this region. The demand for acetazolamide is expected to continue growing, supported by increasing healthcare expenditure and the rising awareness of eye health.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the acetazolamide market.

 

Top 10 Trends in the Acetazolamide Market

1. Surging Demand for Altitude Sickness Prevention
2. Shift Toward 125mg Dosage Formulations
3. Intense Generic Competition and Price Erosion
4. Development of Sustained-Release Technologies
5. Rapid Growth in the Asia-Pacific Region
6. Rise in Chronic Disease Prevalence
7. Repurposing for Novel Indications
8. API Supply Chain Vulnerabilities
9. Expansion in Emerging Markets
10. Focus on Cost-Effective Care

 

1. Surging Demand for Altitude Sickness Prevention

As high-altitude tourism and adventure sports gain popularity, travellers are increasingly using acetazolamide prophylactically. It remains the gold-standard treatment for Acute Mountain Sickness (AMS) by speeding up acclimatization.

 

       2.Shift Toward 125mg Dosage Formulations

While 250mg was traditionally common, there is a clinical shift toward low-dose 125mg formulations. This dosage is often preferred for altitude prophylaxis as it provides efficacy while significantly minimizing side effects like paresthesia (tingling in extremities) and polyuria.

 

       3.Intense Generic Competition and Price Erosion

Acetazolamide is a long-established drug with many generic players. The market faces heavy price pressure as manufacturers compete on cost, leading to thinner profit margins despite steady volume demand.

 

       4. Development of Sustained-Release Technologies

To improve patient compliance and reduce the "peaks and troughs" of drug concentration, manufacturers are focusing on extended-release capsules (e.g., 500mg SR). These are particularly beneficial for glaucoma patients who require consistent intraocular pressure control with fewer daily doses.

 

       5. Rapid Growth in Asia-Pacific Region

Rising healthcare expenditures and a large patient pool with glaucoma (particularly in China and India), this region is seeing the fastest CAGR. Increased awareness of altitude sickness among the growing middle-class traveling to high-altitude destinations in Asia further fuels this trend.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the acetazolamide market.

 

Empower your strategic planning:

Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the acetazolamide market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.

 

Top 20 Companies Leading the Acetazolamide Market

1. Teva Pharmaceutical Industries Ltd.
2. Taro Pharmaceutical Industries Ltd.
3. Sun Pharmaceutical Industries Ltd
4. Lannett Company Inc.
5. Viatris Inc.
6. Aurobindo Pharma Ltd
7. Accord Healthcare, Ltd
8. Strides Pharma Science, Ltd
9. Heritage Pharmaceuticals, Inc.
10. Pfizer Inc.
11. Epic Pharma
12. Glenmark Pharmaceuticals, Inc.
13. Dr Reddy’s Laboratories Ltd
14. Alkem Laboratories
15. Zydus Lifesciences Ltd
16. Shanghai Sine Pharmaceutical
17. Tianjin Lisheng Pharmaceutical
18. Gansu ChenGee Bio-Pharmaceutic
19. Zhejiang Yatai Pharmaceutical
20. Suzhou Homesun Pharmaceutical
21. Other

 

1. Teva Pharmaceutical Industries Ltd

Headquarters: Tel Aviv, Israel

Teva Pharmaceutical Industries Ltd (Teva) is a pharmaceutical company engaged in the development, production, and marketing of generic and innovative medicines. Teva is the 26th largest pharmaceutical company in the world. Teva focus on innovative medicine for various therapeutic areas, including neuroscience and immunology. Teva specializes primarily in generic drugs, but other business interests include branded drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform. Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced the launch of the first and only generic version of Sandostatin1 LAR Depot in the United States.

 

        2. Taro Pharmaceutical Industries Ltd

Headquarters: Haifa, Israel.

Taro Pharmaceutical Industries is an Israeli research-based pharmaceutical manufacturer that was publicly listed on the New York Stock Exchange before it was acquired by Sun Pharma. The company has more than 180 of its own drugs sold all over the world, reaching the markets of over 25 countries. Taro is a research-based international pharmaceutical company that was established on the principle that research and development would be the cornerstone of its growth strategy. Taro Pharmaceutical is now a privately held company wholly owned by Sun Pharma, a global healthcare company with innovative therapies, generic medicines and consumer healthcare products.

 

        3. Sun Pharmaceutical Industries Ltd

Headquarters: Mumbai, India.

Sun Pharmaceutical Industries Limited (d/b/a Sun Pharma) is an Indian multinational pharmaceutical company headquartered in Mumbai. Sun Pharma is India’s No. 1 pharmaceutical company and a leading global player in specialty medicines. With over 40 manufacturing facilities and a diverse portfolio, we deliver high-quality medicines across 100 countries. The US and India are the largest markets, accounting for over 60% of the company's turnover.[6] Manufacturing is across 43 locations in India, the US, Asia, Africa, Australia and Europe.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the acetazolamide market.

 

        4. Lannett Company Inc.

Headquarters: Trevose, Pennsylvania, USA

Lannett Company, Inc. is a U.S.-based pharmaceutical company that develops, manufactures, and distributes generic prescription drugs. It primarily focuses on producing affordable alternatives to brand-name medications. In 2025, Aurobindo Pharma announced plans to acquire Lannett for about $250 million, aiming to expand its manufacturing presence in the U.S. generic drug market. Lannett is a manufacturer of complex generics, including DEA-controlled substances, and has launched products in the liquid and ADHD treatment categories

 

        5.Viatris Inc.

Headquarters: Canonsburg, Pennsylvania, USA

Viatris Inc. is a global pharmaceutical and healthcare company that develops, manufactures, and distributes generic medicines, branded drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company focuses on improving access to affordable medicines worldwide.  In 2023, Viatris divested its biosimilars portfolio to Biocon Biologics and reached agreements to sell its over-the-counter (OTC) and women's healthcare businesses to focus on higher-margin areas

 

Are you ready to discover more about the acetazolamide market?

The report provides an in-depth analysis of the leading companies operating in the global acetazolamide market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the acetazolamide market.

 

Company Profiles

1. 1. Teva Pharmaceutical Industries Ltd.
2. 1. Business Overview
3. Company Snapshot
4. Products Overview
5. Company Market Share Analysis
6. Company Coverage Portfolio
7. Financial Analysis
8. Recent Developments
9. Merger and Acquisitions
10. 2. Taro Pharmaceutical Industries Ltd.
11. 3. Sun Pharmaceutical Industries Ltd
12. 4. Lannett Company Inc.
13. 5. Viatris Inc.
14. 6. Aurobindo Pharma Ltd
15. 7. Accord Healthcare, Ltd
16. 8. Strides Pharma Science, Ltd
17. 9. Heritage Pharmaceuticals, Inc.
18. 10. Pfizer Inc.
19. 11. Other
20.  

Conclusion

The global acetazolamide market is driven by the rising geriatric population, which is more susceptible to conditions treatable with Acetazolamide, further amplifying market demand. Additionally, expanding research into novel therapeutic applications and the development of combination therapies are expected to enhance market penetration.  North America is the largest growing market in acetazolamide, and the Asia Pacific is the fastest growing market in acetazolamide.